Development Path Templates
Development paths are model-structure templates under an asset/program's indication plan. They classify whether a plan is baseline, a structural template, analyst-confirmed, or display-only. The path label itself does not change probability of success, revenue, cost, duration, or launch timing; only explicit, visible, cited assumptions can change scenario math.
What development paths mean
A path is structure and disclosure, not hidden valuation math.
Development paths sit under an asset/program's indication plan: Asset / Program → Indication Plan → Development Path → Scenario. The path records the planned clinical/regulatory route for one indication, patient segment, geography, or branch.
The path label itself has no numeric force. It tells a reviewer what has to be checked before a scenario can apply launch timing, cost, revenue, or population effects. Those effects must be explicit, visible, and cited at the branch or scenario level.
Automatic-effect policy
No development path currently earns a path-based PoS multiplier.
Path labels do not change probability of success, revenue, cost, duration, or launch timing by default. Unsupported branch-effect keys are stripped before application, including any attempted path-based PoS multiplier.
The evidence base supports treating these routes as different regulatory and clinical-development structures. It does not support a universal, indication-agnostic numeric uplift or haircut just because a label says accelerated, adaptive, basket, bridging, or expansion.
Tier policy
The tier tells reviewers how much automatic meaning the template is allowed to carry.
| Tier | Automatic policy | Meaning |
|---|---|---|
| Baseline | No default effect | The comparator path. It supplies ordinary sequencing metadata and does not change valuation assumptions. |
| Structural template | Explicit structural only | The template exposes required review fields and structural flags, but numeric effects remain empty unless entered explicitly. |
| Analyst-confirmed | Analyst confirmed only | The literature supports the path as a distinct clinical design, but effects are bidirectional and asset-specific. |
| Display-only | No default effect | Custom narrative/organization only. It has no model effect until every assumption is entered with rationale. |
Path templates
Allowed meaning and prohibited default effects for each shipped template.
| Path type | Tier | May do | May not do by default |
|---|---|---|---|
| standard_sequential | Baseline | Records the ordinary phase sequence and serves as the no-path-effect comparator. | No path-specific PoS, timing, revenue, or cost effect. |
| accelerated_approval | Structural template | Records accelerated-approval structure, confirmatory obligation, surrogate-endpoint basis, and withdrawal exposure. | No generic launch pull-forward, PoS uplift, commercial haircut, or confirmatory-trial cost default. |
| label_expansion | Structural template | Records supplemental filing structure and requires incremental population/revenue net of the base indication. | No automatic revenue uplift, PoS uplift, or exclusivity benefit. |
| adaptive_design | Analyst-confirmed | Records interim decision rules, enrichment, sample-size re-estimation, or population narrowing. | No automatic cost reduction, duration reduction, sample-size effect, or PoS effect. |
| basket_or_umbrella | Analyst-confirmed | Records multi-cohort structure, common-control logic, cohort pruning, and registration-supporting cohort assumptions. | No automatic market-size haircut, cohort attrition, revenue change, cost change, or tumor-agnostic filing effect. |
| bridging_or_regional | Analyst-confirmed | Records geography, foreign-data package, regional bridge requirement, MRCT context, and partner-led assumptions. | No automatic regional launch acceleration, revenue haircut, bridge-study cost, or probability effect. |
| custom | Display-only | Stores a user-defined route for disclosure and branch organization. | No effect of any kind until the analyst enters explicit assumptions. |
Evidence rationale
Source support is structural; numeric defaults require separate validation.
FDA guidance describes accelerated approval, adaptive designs, and master protocols as clinical-development routes with design-specific obligations and evidentiary requirements. Supplemental-indication and multi-indication oncology studies show that approval routes and post-approval timelines vary materially across products.
That is enough to make development paths meaningful as model-structure templates. It is not enough to ship a generic path-based PoS, duration, revenue, or cost multiplier. Future numeric defaults would require a new version, a cited estimand, and a held-out validation gate comparable to the PoS multiplier discipline.
Signed-export disclosure
Reviewers should see the path policy before trusting the number.
Machine and signed-export surfaces should expose the path label, tier, automatic effect policy, explicit branch effects, analyst overrides, and citations. If no explicit effect exists, the path is disclosure-only.
This keeps path semantics useful without forcing a reviewer to infer whether a hidden adjustment changed the scenario output. The numeric model remains deterministic and inspectable: branch effects are visible inputs, not label side effects.
References
Verified official guidance and DOI-resolved journal sources.
- 01U.S. Food and Drug Administration (2026). Accelerated Approval Program
- 02U.S. Food and Drug Administration (2019). Adaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry
- 03U.S. Food and Drug Administration (2022). Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics Guidance for Industry
- 04International Council for Harmonisation / European Medicines Agency (1998). ICH E5(R1): Ethnic factors in the acceptability of foreign clinical data
- 05Dhodapkar et al. (2021). Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019 doi:10.1001/jamanetworkopen.2021.13224
- 06Dhodapkar, Ross, and Ramachandran (2023). US Food and Drug Administration Review Time of Supplemental New Indication Approvals of Drugs and Biologics, 2017 to 2019 doi:10.1001/jamanetworkopen.2023.18889
- 07Park et al. (2019). Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols doi:10.1186/s13063-019-3664-1
- 08Patterson et al. (2025). Subsequent Indications in Oncology Drugs: Pathways, Timelines, and the Inflation Reduction Act doi:10.1007/s43441-024-00706-6
Development-path templates are methodology disclosure and model-structure metadata. They do not constitute medical, regulatory, financial, or legal advice. Eligibility for accelerated approval, adaptive design acceptability, bridging, exclusivity, and supplemental approval strategy must be confirmed against the asset-specific record.